The online CME search engine.

Strategies for Optimizing RAASi Therapy in Patients with Heart...

Provided by:

Course Description

Hyperkalemia is frequently seen in patients with chronic renal failure, chronic kidney disease, and in patients with acute or chronic kidney disease complicated by drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) system. The treatment of hyperkalemia varies depending on the severity and accompanying symptoms and comorbidities. In 2015, the US Food and Drug Administration approved patiromer a high capacity, oral potassium binder currently for the treatment of hyperkalemia. Other new treatments such as sodium zirconium cyclosilicate (ZS-9) are in development and may provide alternatives to practitioners caring for patients with hyperkalemia.

Ratings and Reviews

To review this course, please login.

Please Review This Course

Overall Quality

Instructor

Usefulness

150 Characters Minimum

Submit
Course Information

Overall Quality

(0)

Instructor

(0)

Usefulness

(0)
Add to Transcript Write Review

Learning Format 1 Hours
Self-Study

Credit Type(s)
Cardiology